You are now visiting tipharma.com.
On 1 January, 2016, TI Pharma and CTMM merged
to form a new organization called Lygature.
Please note that information on the tipharma.com site has not
been updated since, and is retained as an archive.
For up-to-date information, please visit lygature.org.
Even though regulatory bodies like the EMA and FDA cannot work in tandem with industry and academia, they do share a common goal: to develop and launch new drugs that improve society's wellbeing.
TI Pharma brings all stakeholders to the same table. It acts as a neutral platform where common ground can be created and conflicting interests can be mediated, jointly working towards an improved and innovation-friendly regulatory framework.
TI Pharma enables several such partnerships, including:
“Running public-private partnerships is a profession by itself. TI Pharma is an excellent example of how you can do this in an effective way.”
Director/Secretary of the Medicines Evaluation Board